NCT04434196View on ClinicalTrials.gov

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 21, 2020

Primary Completion Date

May 21, 2024

Study Completion Date

May 21, 2024

Conditions
Lymphoma, Non-Hodgkin
Interventions
DRUG

CC-99282

CC-99282

DRUG

Obinutuzumab

Obinutuzumab

Trial Locations (15)

1090

Local Institution - 402, Vienna

5020

Local Institution - 401, Salzburg

6020

Local Institution - 403, Innsbruck

28027

Local Institution - 306, Madrid

28041

Local Institution - 301, Madrid

31008

Local Institution - 304, Pamplona

37007

Local Institution - 303, Salamanca

43210

Local Institution - 104, Columbus

46010

Local Institution - 305, Valencia

75390

Local Institution - 107, Dallas

02215

Local Institution - 106, Boston

97201-3098

Local Institution - 101, Portland

M5G 2M9

Local Institution - 201, Toronto

H3T 1E2

Local Institution - 202, Montreal

08035

Local Institution - 302, Barcelona

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT04434196 - A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Biotech Hunter | Biotech Hunter